Mytocel MSKUnited Kingdom
Gloved hands administering an injection into a patient’s knee

Indications and patient selection

Documented for early to moderate cartilage disease.

Manufacturer-documented indications for Mytocel MSK®: knee osteoarthritis grade I to III (Kellgren-Lawrence), focal cartilage injury or damage, chondromalacia patellae.

Request UK pricingRead the evidence

Documented indications

Where the protocol is documented, and how far it extends.

Explainer plate showing where Mytocel MSK may be considered: knee cartilage and osteoarthritis, shoulder and soft tissue, elbow tendinopathy, and ankle and tendon injuries, with the note that suitability depends on diagnosis, imaging and clinical assessment.
Illustrative representation of the joints where the protocol may be considered; suitability remains a clinical judgement

  • Knee osteoarthritis grade I to III

    Manufacturer-documented primary indication: knee osteoarthritis grade I to III (Kellgren-Lawrence). All four published clinical series are in the knee (combined n = 37), including a three-year follow-up series (n = 8).

    Peer-reviewed clinical1

  • Focal cartilage injury or damage

    Manufacturer-documented indication: focal cartilage injury or damage, where the joint preserves at least part of the articular cartilage.

    Manufacturer-documented, no published clinical series2

  • Chondromalacia patellae

    Manufacturer-documented indication: chondromalacia patellae.

    Manufacturer-documented, no published clinical series3

  • Hip, shoulder and ankle

    The manufacturer states the protocol may be extended to the hip, shoulder and ankle using the same selection criteria; the published clinical series are in the knee.

    Manufacturer-documented, no published clinical series2

  • Tendinopathy and soft-tissue injury

    The manufacturer also describes use in tendinopathy and soft-tissue injury; no published musculoskeletal series in the supplied library addresses this.

    Manufacturer-documented, no published clinical series4

Not indicated in grade IV

Not indicated where articular cartilage is absent (grade IV). The protocol requires that the joint preserves at least part of the articular cartilage.

Exclusions

Who the protocol excludes.

The professional protocol excludes the following. Patient selection, consent and follow-up remain with the treating clinician.

  • Inflammatory rheumatism (positive ANA, ASLO > 150, positive rheumatoid factor, history of inflammatory rheumatism)
  • Morbid obesity
  • Uncontrolled diabetes
  • Severe metabolic disease
  • Grade IV osteoarthritis
  • Corticosteroid or intra-articular injection within the previous 3 months

Full criteria in the professional protocol and the instructions for use.

Selection

The treating clinician decides.

Patient selection, consent and follow-up remain with the treating clinician.

Safety profile
Gloved hands attaching a syringe to the single-use Rigeneracons RS device against a plain blue background.
Preparing the single-use device before the processing cycle

References

  1. 1.Marcarelli M, Zappia M, Rissolio L, et al. Cartilage micrografts as a novel non-invasive and non-arthroscopic autograft procedure for knee chondropathy: three-year follow-up. J Clin Med. 2021;10(2):322. View source
  2. 2.Remedi (Regenera Activa). Mytocel MSK professional protocol. Manufacturer document. View source
  3. 3.Remedi. Mytocel MSK healthcare professional brochure. Manufacturer document. View source
  4. 4.Remedi. Mytocel MSK frequently asked questions. Manufacturer document. View source

Bring Mytocel MSK to your clinic.

Actomed supplies Mytocel MSK in the UK with structured onboarding, first-case support and KOOS templates for structured local outcome collection.

Request UK pricingTraining and support